

Haematologica  
HAEMATOL/2019/231027  
Version 3

Prognostic impact of prevalent chronic lymphocytic leukemia  
stereotyped subsets: analysis within prospective clinical trials of the  
German CLL Study Group (GCLLSG)

Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoehstetter, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Michael Hallek, Hartmut Döhner, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos, and Stephan Stilgenbauer

Disclosures: SJ, CS, KS, AA, JB, SR, HD, VG, KF, MH report no relevant conflicts of interest. MH has received research funding and honoraria from Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, and AbbVie. SS has received research grants, honoraria for consultancy, advisory board member and speaker honoraria, as well as travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis, and Pharmacyclics. BE has received honoraria as speaker bureau from Roche, Novartis, Gilead, Janssen, Abbvie and Celgene, was part of the advisory boards of Janssen, Gilead, Roche, Abbvie, Novartis and Celgene and received research support from Roche, Janssen, Abbvie and Gilead. RR has received honoraria as speaker bureau from Illumina, Roche, Abbvie, and Janssen. PG received honoraria from AbbVie, Acerta(AstraZeneca, BeiGene, Celgene/Juno, Gilead, Janssen, Sunesis and research funding from AbbVie, Gilead, Janssen, Novartis. JB has received travel grants and honoraria from Roche. ET report research support from Novartis.

Contributions: SJ and SS designed the study. KS, PG, and AA did and interpreted molecular analyses. JB, KF, BE, and SR collected and analyzed clinical and performed statistical analysis. ET, CS, and JB were responsible for FISH analyses and immunophenotyping. SJ and SS wrote the first draft of the manuscript. All authors interpreted the data, and all authors read and contributed to the final version of the manuscript.